PharmaJet partner Zydus Cadila seeks EUA on world’s first plasmid DNA COVID-19 vaccine
By: Colorado BioScience Association Date: 07/07/2021
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D, will be exclusively administered using the PharmaJet Tropis® Needle-free Injection System. Zydus Cadila is a global pharmaceutical company based in India, that develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines.
The ZyCoV-D vaccine is the first ever plasmid DNA vaccine for human use and represents a key milestone in scientific innovation and technology advancement. It is delivered intradermally using the PharmaJet Tropis Needle-free Injection System, which enables enhanced vaccine effectiveness in addition to being highly preferred by patients and providers over other delivery methods. The DNA platform is ideally suited for a COVID-19 vaccine as it can be easily adapted to deal with mutations in the virus and has greater thermostability and less restrictive cold chain requirements compared with other vaccines.
ZyCoV-D administered with the PharmaJet® Tropis® Needle-free device has already established a robust immunogenicity and tolerability and safety profile with its 66.6% efficacy for RT-PCR positive cases in the interim analysis. No moderate cases of COVID-19 were observed in the Doc. #60-10361-054 Rev. AR vaccine arm post administration of its third dose, clocking a 100% efficacy for moderate disease. In addition to adults, the vaccine is safe for adolescents 12 to 18 years of age.
Chris Cappello, President and CEO, PharmaJet, said, “We are pleased to be partnering with Zydus Cadila as they move forward with plans to commercialize the first ever DNA vaccine for COVID-19. We are prepared operationally to supply our delivery systems to help support the fight against COVID-19 and its variants in India and beyond.”
Find out more in the PharmaJet press release.
For more information about PharmaJet visit www.pharmajet.com.